Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Incretins such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are intestinal postprandial hormones that stimulate insulin release from the pancreas as long as circulating glucose concentrations are raised. In addition to their effect on insulin secretion and consequent glucose lowering, GIP and GLP-1, especially the latter, have a number of physiological effects such as inhibition of glucagon release, gastric emptying and food intake, as well as a tropic action on pancreatic B-cell mass. There is currently a pandemic of obesity and diabetes, and existing treatments are largely inadequate both in regard to efficacy as well as their ability to tackle important factors in the pathogenesis of type 2 diabetes (T2D). There is increasing evidence that current treatments do not address the issue of progressive B-cell failure in T2D. Since obesity is the engine that is driving the epidemic of diabetes, it is disappointing that most treatments that succeed in lowering plasma glucose are also associated with weight gain. It is now well established that intensively treated T2D has a better outcome than standard treatment. Consequently, achieving better control of diabetes with lower HbA1c is the goal of optimal treatment. Despite the use of usual therapeutic agents in T2D, often in high doses and as combinations, such as metformin, sulphonylurea, α-glycosidase inhibitors, thiazolidinediones and a number of animal and human insulin preparations, optimal control of glycaemia is not achieved. The use of incretins as therapeutic agents offers a new approach to the treatment of T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Studies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Research works printed but not linked: 52
- 10.2337/diacare.21.9.1414 · DOI · Paper page
- 10.1136/bmj.321.7258.405 · DOI · Paper page
- 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
- 10.2337/diacare.27.1.17 · DOI · Paper page
- 10.1016/S0140-6736(02)83547-4 · DOI
- 10.1139/v71-145 · DOI · Paper page
- 10.1016/0014-5793(87)81430-8 · DOI · Paper page
- Creutzfeldt, 1988, The incretin concept., Adv Metab Disord, 11, 333, 10.1016/B978-0-12-027311-9.50014-7 · DOI
- Habener, 1993, The incretin notion and its relevance to diabetes., Endocrinol Metab Clin North Am, 22, 775, 10.1016/S0889-8529(18)30135-X · DOI
- 10.1210/edrv-16-3-390 · DOI · Paper page
- Morgan LM . Insulin secretion and the enteroinsular axis. In: Flatt PR , ed. , ed. Nutrient regulation of insulin secretion. London: Biochemical Society, Portland Press, 1992:1–22.
- 10.2337/diab.44.9.1126 · DOI · Paper page
- 10.1002/(SICI)1096-9136(199802)15:2<120::AID-DIA529>3.0.CO;2-I · DOI · Paper page
- 10.1016/S0899-9007(99)00238-5 · doi:10.1016/s0899-9007(99)00238-5
- 10.1046/j.1365-2362.1999.00426.x · DOI
- 10.1002/(SICI)1520-7560(199911/12)15:6<390::AID-DMRR67>3.0.CO;2-W · DOI
- 10.2337/diab.47.8.1259 · DOI · Paper page
- 10.1007/s00125-003-1203-8 · DOI
- 10.1007/BF00401846 · DOI · Paper page
- 10.1210/en.141.12.4600 · DOI · Paper page
- 10.1210/me.2002-0306 · DOI · Paper page
- 10.1055/s-2004-826164 · DOI
- Naslund, 1999, GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans., Am J Physiol, 277, R910
- 10.1210/endo-126-1-110 · DOI
- 10.1056/NEJM198106183042504 · DOI · Paper page
- 10.1592/phco.22.7.436.33667 · DOI
- Nauck, 2004, Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes., Diabetes, 53, S190, 10.2337/diabetes.53.suppl_3.S190 · DOI · Paper page
- 10.1046/j.1464-5491.2000.00367.x · DOI · Paper page
- 10.1177/0145721706294259 · DOI · Paper page
- 10.2337/diacare.29.03.06.dc05-1703 · DOI
- 10.2165/00024677-200302010-00004 · DOI
- 10.1172/JCI113157 · DOI · Paper page
- Horowitz M Dent J Fraser R . Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994;39(12 Suppl):7S–13S. · DOI
- Phillips, 1992, Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients., J Nucl Med, 33, 1496
- 10.1210/jc.86.8.3717 · DOI · Paper page
- 10.1152/ajpendo.00545.2003 · DOI · Paper page
- 10.1042/cs0990093 · DOI
- 10.1042/CS20040302 · DOI · Paper page
- 10.1046/j.1432-1327.2000.01634.x · DOI · Paper page
- 10.2337/diabetes.53.2007.S82 · DOI
- 10.2337/diabetes.52.3.741 · DOI · Paper page
- 10.1210/jc.2003-031907 · DOI · Paper page
- 10.2337/diabetes.51.2.424 · DOI · Paper page
- Nauck, 2004, Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes., Diabetes, 53, A83
- 10.2337/diabetes.53.9.2397 · DOI · Paper page
- Nauck, 2003, No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2 diabetes., Diabetes, 52, A128
- 10.1016/j.regpep.2003.10.028 · DOI · Paper page
- Amylin Pharmaceuticals, Inc. Byetta (exenatide) package insert. San Diego, CA: Amylin, 2005 (www.byetta.com). · DOI
- 10.1002/dmrr.499 · DOI · Paper page
- 10.1055/s-2005-870529 · DOI · Paper page
- 10.1111/j.1463-1326.2005.00539.x · DOI · Paper page
- 10.1016/j.clinthera.2006.10.007 · DOI · Paper page
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“491 In the brain, it reduces appetite and improves satiety.”
BackgroundPipatpiboon, N., Pintana, H., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12088 · Cited by 183
“…Received 3 April 2012, accepted 9 November 2012 © 2012 Federation of European Neuroscience Societies and Blackwell Publishing Ltd degraded by a dipeptidyl peptidase-4 (DPP-4) enzyme in the circulation (Drucker & Nauck, 2006; Davidson et al., 2008; Ranganath, 2008; Akarte et al., 2011).”
BackgroundBello, N. T., Kemm, M. H., Ofeldt, E. M., & Moran, T. H. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00275.2010 · Cited by 66
Metadata
- Authors
- Ranganath, L. R.
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2008-03-28
- Volume
- 61
- Issue
- 4
- Pages
- 401-409
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W2093088114
- Cited by
- 66
- References
- 21
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.